John Hanna, MD
Vascular Neurology · Summit, NJNPI 1922396266
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,113 of the $3,380 with a category attached, or 62.5%. Medtronic accounts for 64.2% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $1,659 and has fallen 96.9% since, to $51 in 2024.
Across 67 payments — averaging $50.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Genentech USA, Inc.$127
- Biogen$126
- Teva Pharmaceuticals USA, Inc.$111
- Microtransponder, Inc.$104
- Pfizer$98
- plus $646 from 21 others
Across 10 payments — averaging $3380.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$34K
What the payments were for
- Consulting fees$2,11363%
- Food & beverage$1,11633%
- Education$1514%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 5 | $2,170 |
| Genentech USA, Inc. | 1 | $127 |
| Biogen | 11 | $126 |
| Teva Pharmaceuticals USA, Inc. | 1 | $111 |
| Microtransponder, Inc. | 1 | $104 |
| Pfizer | 6 | $98 |
| Merz North America, Inc. | 4 | $64 |
| Eisai Inc. | 4 | $63 |
| Lilly USA, LLC | 4 | $58 |
| GE HealthCare | 4 | $57 |
| Supernus Pharmaceuticals, Inc. | 4 | $53 |
| E.r. Squibb & Sons, L.L.C. | 1 | $50 |
| AbbVie(2 entities) | 3 | $39 |
| Amneal Pharmaceuticals LLC | 3 | $38 |
| Novartis | 2 | $36 |
| Grifols USA, LLC | 2 | $34 |
| Merck | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Akcea Therapeutics, Inc. | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $13 |
| EMD Serono, Inc. | 1 | $13 |
| UCB, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Lundbeck LLC | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Activase$127
How this compares
Too few vascular neurology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other vascular neurology in Summit
- Kiwon LeeSummit$7K
- Kristine ArandelaSummit$22
- Inder SinghNeptune$119K
- Fred RinconCamden$85K
- Kevin CrutchfieldHackensack$19K
- Peter BarcasNeptune$10K
- Pratit PatelNeptune$3K
- Laura RisleyNeptune$3K
- Gerald FerenczToms River$2K
- Steven ShapiroLivingston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.